
Biogen Shares Rise After Alzheimer's Drug Diranersen Shows Promise in Mid-Stage Trial
The biotechnology company plans to advance its experimental Alzheimer's treatment, diranersen, to a Phase 3 study after Phase 2 data showed it slowed cognitive decline and reduced key tau biomarkers.







